Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - dutasteride, quantity: 500 microgram - capsule, soft - excipient ingredients: titanium dioxide; gelatin; glycerol; iron oxide yellow; butylated hydroxytoluene; glyceryl caprylate/caprate; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - this medicine is indicated for use as monotherapy for the management of symptomatic benign prostatic,hyperplasia (bph) or as combination therapy with an alpha blocker which is approved for use in bph and,which has been dose titrated in accordance with the relevant recommendations in the product information,for that alpha blocker.

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tabletsare not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tabletsare contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [s ee use in specific populations (8.7) and clinical pharmacology (12.3 )]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [ see drug interactions (7.1 ) and clinical pharmacology (12.3 )] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzosin hydrochloride extended-release tablets [see

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

Stati Uniti - inglese - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1)and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of al

Stati Uniti - inglese - NLM (National Library of Medicine)

golden state medical supply, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, a

Australia - inglese - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram; tamsulosin hydrochloride, quantity: 400 microgram - capsule, modified release - excipient ingredients: maize starch; carrageenan; gelatin; purified talc; butylated hydroxytoluene; iron oxide yellow; titanium dioxide; iron oxide red; glycerol; medium chain triglycerides; potassium chloride; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); purified water; triethyl citrate; lecithin; glyceryl caprylate/caprate; sunset yellow fcf; carnauba wax; hypromellose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - doubluts is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (bph).

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - alfuzosin hydrochloride - tablet prolonged release - 10 milligram

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - alfuzosin hydrochloride - prolonged-release tablet - 10 milligram(s) - alpha-adrenoreceptor antagonists; alfuzosin

Israele - inglese - Ministry of Health

padagis israel agencies ltd, israel - alfuzosin hydrochloride - tablets prolonged release - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.